Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
MRD
Advertisement
Hansa Biopharma Reports Positive Idefirix Results
LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...
TransCode Starts Phase 2a Trial for TTX-MC138
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
CareDx Acquires Naveris to Expand Precision Oncology
BRISBANE, CALIFORNIA, April 28, 2026 CareDx Inc. has announced a definitive agreement to acquire Naveris, marking a significant expansion...
Foundation Medicine Expands MRD Platform with SAGA Deal
BOSTON, April 16, 2026 Foundation Medicine, Inc. has announced a major expansion of its oncology diagnostics portfolio through the...
Advertisements
NeoGenomics Advances AI-Driven Oncology Insights at AACR
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
Natera Strengthens MRD Leadership With Acquisition of Foresight Diagnostics
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
Bristol Myers Squibb’s Iberdomide Shows Strong Phase 3 Results in Multiple Myeloma
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
Foresight Diagnostics Demonstrates Ultrasensitive MRD Detection in Early-Stage Lung Cancer at IASLC 2025
Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, presented new clinical performance data on its Foresight...
Advertisement
